Bioadaptives, Inc. (BDPT) Financial Statements (2026 and earlier)

Company Profile

Business Address 2620 REGATTA DRIVE
LAS VEGAS, NV 89128
State of Incorp. DE
Fiscal Year End December 31
Industry (SIC) 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete Financial Analysis Financial Benchmarking

Balance Sheet (Statement of Financial Position) ($ in thousands)
Annual | Quarterly

3/31/2026
MRQ
12/31/2025
12/31/2024
12/31/2023
12/31/2022
12/31/2021
12/31/2020
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments 2152626125835
Cash and cash equivalent 2152626125835
Short-term investments    000
Inventory, net of allowances, customer advances and progress billings4519159514
Inventory4519159514
Prepaid expense610010 1 
Other undisclosed current assets(54)(119)3   
Total current assets:21226289348919
Noncurrent Assets
Property, plant, and equipment, after accumulated depreciation, depletion, and amortization      
Intangible asset, including goodwill, after accumulated amortization 14 15360 
Intangible asset, excluding goodwill, after accumulated amortization 14 15360 
Other undisclosed noncurrent assets   0   
Total noncurrent assets:14 15360 
TOTAL ASSETS:2262621043714919
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities, including:23317944441024888
Accounts payable14637  
Accrued liabilities2162138163 
Other undisclosed accounts payable and accrued liabilities317230240218588
Debt352311322382403405
Derivative instruments and hedges, liabilities1,7391,053978687557827
Due to related parties✕✕✕✕103478
Other undisclosed current liabilities321828   
Total current liabilities:2,3561,7261,7511,4891,2421,398
Noncurrent Liabilities
Total liabilities:2,3561,7261,7511,4891,2421,398
Equity
Equity, attributable to parent, including:(2,130)(1,464)(1,647)(1,452)(1,093)(1,379)
Common stock11902552
Common stock, share subscribed but unissued, subscriptions receivable(6)(6)    
Additional paid in capital8,5967,7046,5276,0755,5584,225
Accumulated deficit(10,721)(9,163)(8,264)(7,552)(6,656)(5,606)
Other undisclosed equity, attributable to parent00100 
Total equity:(2,130)(1,464)(1,647)(1,452)(1,093)(1,379)
TOTAL LIABILITIES AND EQUITY:2262621043714919

Income Statement (P&L) ($ in thousands)
Annual | Quarterly

3/31/2026
TTM
12/31/2025
12/31/2024
12/31/2023
12/31/2022
12/31/2021
12/31/2020
Revenues181329172016
Other income 5    
Cost of revenue(6)(9)(18)(10)(10)(10)
Gross profit:124117106
Operating expenses(1,055)(606)(240)(429)(646)(260)
Other operating expense, net
(Other Expenses)		     (414)(593)
Operating loss:(1,042)(602)(229)(422)(1,050)(847)
Nonoperating income (expense)(516)(297)(484)(474)1,376 
Gain on sale of leased assets, net, operating leases     1,286 
Other nonoperating expense(516)(297)(484)(474)  
Interest and debt expense(44)(38)(13)(289)(323)133
Income (loss) from continuing operations before equity method investments, income taxes:(1,602)(937)(726)(1,185)3(715)
Other undisclosed income (loss) from continuing operations before income taxes44    (133)
Income (loss) from continuing operations before income taxes:(1,558)(937)(726)(1,185)3(847)
Other undisclosed income from continuing operations  3313289  
Income (loss) from continuing operations:(1,558)(905)(712)(896)3(847)
Income (loss) before gain (loss) on sale of properties:✕✕✕✕✕3(847)
Other undisclosed net income  6    
Net income (loss):(1,558)(899)(712)(896)3(847)
Other undisclosed net loss attributable to parent     (1,053) 
Net loss attributable to parent:(1,558)(899)(712)(896)(1,050)(847)
Preferred stock dividends and other adjustments     194 
Net loss available to common stockholders, basic:(1,558)(899)(712)(896)(856)(847)
Interest on convertible debt  5612  
Net loss available to common stockholders, diluted:(1,558)(894)(706)(884)(856)(847)

Comprehensive Income ($ in thousands)
Annual | Quarterly

3/31/2026
TTM
12/31/2025
12/31/2024
12/31/2023
12/31/2022
12/31/2021
12/31/2020
Net income (loss):(1,558)(899)(712)(896)3(847)
Comprehensive income (loss), net of tax, attributable to parent:(1,558)(899)(712)(896)3(847)

Statements Sources

The financial statements are based on the Company's filings with the U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: